(Q33851581)

29 July 2017

1 reference

title

Angiotensin II receptor antagonists. (English)

1 reference

29 July 2017

M Burnier

1

1 reference

PubMed ID

10696996

29 July 2017

H R Brunner

series ordinal

2

1 reference

PubMed ID

10696996

29 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

29 July 2017

1 reference

29 July 2017

355

1 reference

29 July 2017

9204

1 reference

29 July 2017

637-645

1 reference

Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

15 years of heart-failure trials: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Current strategies for retarding progression of renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Human renin inhibitor peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Clinical pharmacology of ACE inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Plasma bradykinin in angio-oedema.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Human angiotensin receptor subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Cloning and characterization of a human angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Pharmacology of valsartan, an angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

1 reference

7 January 2021

Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Comparative safety and tolerability of angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Angioedema induced by the angiotensin II blocker losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Angioneurotic edema attributed to the use of losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Renal impairment associated with losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Reversible acute renal failure induced by losartan in a renal transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Anaemia in dialysis patients as a side-effect of sartanes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Renal effects of angiotensin II receptor blockade in normotensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Effects of losartan on a background of hydrochlorothiazide in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2910365-9

7 January 2021

10.1016/S0140-6736(99)10365-9

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10696996